Breaking News
Get 40% Off 0
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now
Close

Milestone (MMD)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
1.58 0.00    0.00%
18/12 - Closed. Currency in PLN ( Disclaimer )
Type:  Equity
Market:  Poland
ISIN:  USU6005B1045 
  • Volume: 0
  • Bid/Ask: 1.50 / 1.58
  • Day's Range: 1.50 - 1.58
Milestone 1.58 0.00 0.00%

Milestone Company Profile

 
Get an in-depth profile of Milestone, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

14

Equity Type

ORD

Milestone Medical, Inc. develops, manufactures, commercializes, and markets intra-articular and epidural drug delivery systems in the United States and Europe. The company’s products are based on computer-controlled injection and drug delivery technology. Its products include dynamic pressure sensing system, a patented computer-controlled injection system that measures the density of body tissue and helps clinician know the location of a hypodermic needle during an injection; and intra-articular injection instrument that is used to inject into various joints in treatment of arthritis and other joint conditions. The company was formerly known as Milestone Scientific Research and Development, Inc. Milestone Medical, Inc. The company was incorporated in 2011 and is based in Roseland, New Jersey. Milestone Medical, Inc. is a subsidiary of Milestone Scientific, Inc.

Contact Information

Address 425 Eagle Rock Avenue Suite 403
Roseland, 07068
United States
Phone 973 535 2717
Fax 973 535 2829

Top Executives

Name Age Since Title
Edward J. Zelnick 77 - Director of Clinical Research & Member of Scientific Advisory Board
Lorrence Howell Green - - Member of Scientific Advisory Board
Jan Adriaan Haverhals 61 2021 CEO & Director
Ralf Erich Gebhard - - Member of Scientific Advisory Board
Mark Hochman 65 2011 Clinical Director, Director of Research & Development and Member of Scientific Advisory Board
Paul J. Davis - - Member of Scientific Advisory Board
Benedetta I. Casamento 56 2023 Director
Neal Ira Goldman 79 2023 Director
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

MMD Comments

Write your thoughts about Milestone
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email